Health Care & Life Sciences » Biotechnology | arGEN-X

arGEN-X N.V. | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
2,677.00
3,756.00
6,854.00
14,713.00
36,415.00
21,482
SG&A Expense
11,363.00
14,586.00
25,364.00
38,233.00
63,742.00
110,587
EBIT
8,807.00
10,964.00
18,706.00
22,057.00
27,762.00
85,842
Unusual Expense
-
1,400.00
-
-
875.00
-
Non Operating Income/Expense
2,191.00
1,419.00
2,674.00
31.00
1,950.00
14,150
Interest Expense
4.00
-
-
-
-
-
Pretax Income
6,434.00
10,808.00
15,920.00
22,015.00
28,462.00
67,998
Income Tax
303.00
494.00
608.00
641.00
386.00
1,357
Consolidated Net Income
6,131.00
10,314.00
15,312.00
21,374.00
28,076.00
66,641
Net Income
6,131.00
10,314.00
15,312.00
21,374.00
28,076.00
66,641
Net Income After Extraordinaries
6,131.00
10,314.00
15,312.00
21,374.00
28,076.00
66,641
Net Income Available to Common
6,131.00
10,314.00
15,312.00
21,374.00
28,076.00
66,641
EPS (Basic)
0.40
1.37
0.97
1.14
1.14
1.99
Basic Shares Outstanding
15,496.40
7,551.60
15,734.00
18,820.60
24,609.50
33,419.40
EPS (Diluted)
0.40
1.37
0.97
1.14
1.14
1.99
Diluted Shares Outstanding
15,496.40
7,551.60
15,734.00
18,820.60
24,609.50
33,419.40
EBITDA
8,686.00
10,830.00
18,510.00
21,722.00
27,327.00
85,349
Other Operating Expense
-
-
-
1,798.00
-
3,756
Non-Operating Interest Income
186.00
137.00
112.00
73.00
375.00
3,694

About arGEN-X

View Profile
Address
Willemstraat 5
Breda Noord-Brabant 4811 AH
Netherlands
Employees -
Website http://www.argen-x.com
Updated 07/08/2019
argenx SE is a clinical-stage biotechnology company, which engages in the research and development of human monoclonal antibodies for the treatment of cancer and oncological, autoimmune, and inflammatory diseases. Its products include ARGX-113 for severe autoimmune diseases and ARGX-110 for T-cell lymphoma and acute myeloid leukemia. It operates through the following geographical segments: Netherlands, Belgium, Germany, Denmark, Switzerland, United States, and Luxemburg.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.